Skip to main content
. Author manuscript; available in PMC: 2015 Nov 28.
Published in final edited form as: Vaccine. 2014 Feb 13;32(50):6847–6854. doi: 10.1016/j.vaccine.2014.01.096

Fig. 2.

Fig. 2

Average of the subject’s individual IL-6 Cytokine responses (pg/mL) among all groups of the EBS.AVA.201 Study. Vaccines: AV7909 F1 (AVA 0.5 ml + CpG 0.5 ml); AV7909 F2 (AVA 0.5 ml + CpG 0.25 ml); AV7909 F3 (AVA 0.25 ml + CpG 0.5 ml); AV7909 F4 (AVA 0.25 ml + CpG 0.25 ml); AVA= BioThrax (0.5 mL); placebo (0.5 ml saline). Statistically, IL-6 in serum differed between AV7909 (Formulations 1 – 4) or AVA relative to placebo p < 0.05 following post-hoc analysis using MANOVA. But AVA IL-6 was not different from that in AV7909 Formulations 1–4 (p > 0.05).